Feb 23 (Reuters) - Halozyme Therapeutics Inc :
   * HALOZYME REPORTS FOURTH QUARTER 2020 RESULTS AND FULL YEAR 2020 RESULTS
   * Q4 EARNINGS PER SHARE $0.50
   * Q4 REVENUE $121.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $120.2 MILLION
   * SEES FY 2021 GAAP EARNINGS PER SHARE $1.40 TO $1.55
   * SEES FY 2021 REVENUE $375 MILLION TO $395 MILLION
   * Q4 EARNINGS PER SHARE ESTIMATE $0.53 -- REFINITIV IBES DATA
   * 2021 ROYALTIES PROJECTED TO DOUBLE VERSUS 2020 ROYALTIES
   * PLANS TO REPURCHASE UP TO $125 MILLION IN COMMON STOCK DURING 2021 AS PART OF $550 MILLION THREE-YEAR SHARE REPURCHASE PLAN
   * FY2021 EARNINGS PER SHARE VIEW $1.70, REVENUE VIEW $400.2 MILLION -- REFINITIV IBES DATA

Source text for Eikon:  Further company coverage:

((Reuters.Briefs@thomsonreuters.com;)